Moderna says vaccine 93% effective for six months after second jab
The drugmaker, which reported its first profit earlier in 2020, says a booster may still be needed to beat Delta variant
Moderna said on Thursday its Covid-19 vaccine remained 93% effective through six months after the second shot, as it reported second-quarter earnings and revenue that beat expectations.
A final analysis of the company’s late-stage study, described in a statement on Thursday, suggests the vaccine’s protection remains stable for long after recipients complete the standard two-dose regimen. The effectiveness level at six months is just short of the shot’s initial efficacy of 94%.
Still, Moderna executives said during a call with investors that they expect efficacy to continue to wane over time, leading to an increase in breakthrough infections among the vaccinated.
“We believe a booster dose is likely to be necessary this fall, particularly in the face of the Delta variant,” president Stephen Hoge said. He noted that the company must still determine the appropriate dosage of the third-shot before approaching US regulators.
Amid concern over waning protection, some countries have already begun to offer vulnerable people third-dose booster shots. However, World Health Organization (WHO) director-general Tedros Adhanom Ghebreyesus called for a moratorium on such measures on Wednesday until more people in the developing world are inoculated.
The shares rose 2.8% in New York on Thursday. Covid-19 vaccine maker Pfizer lost 0.6%, while its partner BioNTech, shed 3.7%. Moderna’s latest efficacy data hasn’t been published in a medical journal and further details weren’t released.
Currently, all three of the company’s booster candidates produced “robust antibody responses” against Delta and other variants of concern in a phase 2 human study, Moderna said in its statement. The boosters are being tested at a 50 microgram dose, or half what is used in the current shot. That data has been submitted to a journal for publication, the company said.
Despite the apparent endurance of its vaccine at six months, Moderna is exploring options for supplemental shots that could fend off emerging strains of the virus.
In the “long-term endemic market”, Hoge said a multivalent shot that immunises against multiple strains of the coronavirus is going to be the best way forward.
Cambridge, Massachusetts-based Moderna also said it expected to complete its submission for full US Food and Drug Administration (FDA) approval for its vaccine in August.
The agency is already reviewing the submission for a rival messenger RNA (mRNA) vaccine from Pfizer and BioNTech, and is under growing pressure to complete the process quickly. With the Delta variant sparking a new wave of cases, advocates say an approval could help convince more people to get a shot.
Moderna, which reported its first profit earlier in 2020, had net income of almost $2.8bn in the quarter ending June 30 on revenue of $4.4bn, almost all of which is from its Covid-19 shot. Diluted earnings per share of $6.46 easily beat analysts expectations, according to a survey of analysts by Bloomberg, while revenue only slightly exceeded expectations.
The company said in the release it has signed $20bn worth of Covid-19 vaccine purchase agreements for 2021, up from the $19.2bn it announced in May. For 2022, it already has signed agreements for $12bn in vaccine sales with options for $8bn more. Moderna didn’t increase its forecast that it will produce 800-million to 1-billion Covid-19 vaccine doses in 2021.
Moderna’s views for total sales of its Covid-19 vaccine pale in comparison to the Pfizer-BioNTech partnership, which has a higher manufacturing capacity for its shot. In July, Pfizer boosted its vaccine sales forecast for 2021 to $33.5bn.
Moderna’s shares have quadrupled since the beginning of the year, and the company hit $100bn in market value for the first time July 14. The stock was made part of the S&P 500 in July and is the index’s best performer this calendar year.
As the biotech seeks to grow further, it will look at opportunities to acquire or license technologies that could enhance its platform. Moderna, which has more than $12bn in cash and investments, will focus on nucleic acid technologies, such as mRNA, gene editing, and gene therapy, the company said in a presentation. CEO Stephane Bancel said Moderna wouldn’t pursue small or large molecule candidates.
Moderna has also built out its suite of leaders to double down on its commercial franchise. In the past quarter, the company hired Paul Burton, a former Johnson & Johnson executive, to serve as chief medical officer, and Ogilvy’s Kate Cronin as chief brand officer.
“We’re just getting started,” Bancel said.
Bloomberg News. More stories like this are available on bloomberg.com
Would you like to comment on this article or view other readers' comments?
Register (it’s quick and free) or sign in now.
Please read our Comment Policy before commenting.